Yttrium‐90 radiation segmentectomy for hepatic metastases: A multi‐institutional study of safety and efficacy
- 17 September 2020
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 123 (1) , 172-178
Abstract
Background and Objectives: This study assessed the outcomes of Yttrium‐90 (90Y) radiation segmentectomy for hepatic metastases unamenable to resection or ablation.Materials and Methods: Over 6 years, 36 patients with 53 tumors underwent segmental radioembolization. Patients were not candidates for surgical resection or thermal ablation. Malignancies included metastases from colorectal cancer (31%), neuroendocrine tumors (28%), sarcoma (19%), and others (22%). Eighty‐one percent of patients had undergone prior treatment with systemic chemotherapy. Ongoing systemic chemotherapy was continued. Toxicity, tumor response, tumor progression, and survival were assessed.Results: The median tumor size was 3.6 cm (range 1.2–6.1 cm). Adverse event rates were low, with no hepatic‐related Common Terminology Criteria for Adverse Events Grade 3 or 4 toxicity. Target tumor Response Evaluation Criteria in Solid Tumors disease control rate was 92% (28% partial response, 64% stable disease). For patients with enhancing tumors (n = 14), modified Response Evaluation Criteria in Solid Tumors target tumor objective response rate was 100%. During a median follow‐up of 12 months, target tumor progression occurred in 28% of treated tumors. Overall survival was 96% and 83% at 6 and 12 months, respectively.Conclusions: 90Y radiation segmentectomy for hepatic metastases demonstrates high rates of tumor control and minimal toxicity. Radiation segmentectomy should be considered for patients with metastatic hepatic malignancy who are not candidates for surgical resection.Keywords
This publication has 43 references indexed in Scilit:
- Liver resection for metastatic melanoma: Equivalent survival for cutaneous and ocular primariesJournal of Surgical Oncology, 2013
- Small Liver Colorectal Metastases Treated with Percutaneous Radiofrequency Ablation: Local Response Rate and Long-term Survival with Up to 10-year Follow-upRadiology, 2012
- Radioembolisation with 90Y-labelled resin microspheres in the treatment of liver metastasis from breast cancerEuropean Radiology, 2012
- Matched-Pair Comparison of Radioembolization Plus Best Supportive Care Versus Best Supportive Care Alone for Chemotherapy Refractory Liver-Dominant Colorectal MetastasesCardioVascular and Interventional Radiology, 2011
- Radiation Segmentectomy: A Novel Approach to Increase Safety and Efficacy of RadioembolizationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus StatementAnnals of Surgical Oncology, 2006
- Extending the Frontiers of Surgical Therapy for Hepatic Colorectal Metastases: Is There a Limit?Journal of Clinical Oncology, 2005
- Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver MetastasesAnnals of Surgery, 2004